MedTrace Logo

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

NCT06126341 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2026-02-19

No results posted yet for this study

Summary

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Conditions

Interventions

OTHER

Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM

Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.

BEHAVIORAL

Hospital Anxiety and Depression Scale

Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire

BEHAVIORAL

Duke-UNC Functional Social Support Questionnaire

A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.

BEHAVIORAL

Distress Thermometer

The Distress Thermometer is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress

BEHAVIORAL

FACT-BMT

The FACT-BMT Version 4.0 is a 37 item self-report questionnaire that measures the effect of cancer on Quality of Life domains

BEHAVIORAL

Psychosocial Assessments of Candidates for Transplantation

The PACT scale is a single page 10-item rating scale with high inter-rater reliability that has been used extensively in solid organ transplantation

Sponsors & Collaborators

Principal Investigators

  • Heather Landau, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-03
Primary Completion
2029-05-03
Completion
2029-05-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06126341 on ClinicalTrials.gov